ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer

EGFR mutation testing is now well established as a means of selecting the optimal first‐line therapy for patients with advanced non‐small‐cell lung cancer (NSCLC). However, deciding on the correct treatment for EGFR wild‐type NSCLC remains a challenge. EGFR fluorescence in‐situ hybridization (FISH)...

Descripción completa

Detalles Bibliográficos
Autores principales: Moecks, Joachim, Soulières, Denis, Klughammer, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939878/
https://www.ncbi.nlm.nih.gov/pubmed/27499899
http://dx.doi.org/10.1002/cjp2.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939878/
https://www.ncbi.nlm.nih.gov/pubmed/27499899
http://dx.doi.org/10.1002/cjp2.15

Ejemplares similares